---
title: "CRISPR Therapeutics AG 1Q 2026: Revenue $1.458M, EPS $(1.28) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285121419.md"
description: "CRISPR Therapeutics AG reported Q1 2026 results with revenue of $1.458M, a net loss of $(122.931) M, and diluted EPS of $(1.28). Revenue increased by 68.5% year-over-year. The company narrowed its net loss from $(135.996) M in Q1 2025. Key highlights include product approvals for CASGEVY, advancements in LNP and SyNTase platforms, and ongoing trials for sickle cell disease and type 1 diabetes. Strategic partnerships with Vertex and Sirius are enhancing co-development efforts. Continued investment in manufacturing and R&D is prioritized across four core franchises."
datetime: "2026-05-04T20:51:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285121419.md)
  - [en](https://longbridge.com/en/news/285121419.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285121419.md)
---

# CRISPR Therapeutics AG 1Q 2026: Revenue $1.458M, EPS $(1.28) — 10-Q Summary

CRISPR Therapeutics AG reported first-quarter 2026 results with revenue of $1.458M and a net loss of $(122.931) M, narrowing from a $(135.996) M loss a year earlier; diluted loss per share improved to $(1.28) from $(1.58) in Q1 2025.

**Financial Highlights**

-   Revenue was $1.458M for Q1 2026, compared with $0.865M in Q1 2025; YoY change 68.5%.
-   Net income was a loss of $(122.931) M for Q1 2026, compared with a loss of $(135.996) M in Q1 2025; loss narrowed $13.065M YoY.
-   Diluted earnings per share was $(1.28) for Q1 2026, compared with $(1.58) in Q1 2025; loss per share narrowed.

**Business Highlights**

-   Product approvals and pipeline momentum: CASGEVY has been approved in multiple major markets; several pivotal and long‑term trials are ongoing for sickle cell disease (SCD) and transfusion‑dependent thalassemia (TDT).
-   In vivo and delivery advances: Progress on LNP and SyNTase platforms with multiple liver‑targeted programs entering IND/CTA‑enabling studies.
-   CAR‑T and regenerative programs: Zugo‑cel is advancing in autoimmune and oncology trials; CTX213 made preclinical progress for type 1 diabetes.
-   Partnerships: Strategic collaborations with Vertex and Sirius are supporting co‑development, commercialization and expansion of siRNA programs.
-   Operational capacity and R&D: Continued investment in internal GMP manufacturing, clinical site expansion and R&D prioritization across four core franchises.

Original SEC Filing: CRISPR Therapeutics AG \[ CRSP \] - 10-Q - May. 04, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CRSP.US](https://longbridge.com/en/quote/CRSP.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [SIRI.US](https://longbridge.com/en/quote/SIRI.US.md)

## Related News & Research

- [Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 | AYTU Stock News](https://longbridge.com/en/news/286813229.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [REEVES CONFIRMS NO INCREASE IN UK FUEL DUTY IN 2026](https://longbridge.com/en/news/287213292.md)